SHPK and systemic lupus erythematosus: A number of venom-derived compounds have been investigated in pre-clinical trials (Pennington et al., 2018; Bordon et al., 2020) or are in more advanced stages of clinical trials such as chlorotoxin derivates for tumour painting in intraoperative visualization (Patil et al., 2019), and the ShK-186 analogue derived from the venom peptide ShK from sea anemone for the treatment of autoimmune diseases such as psoriatic arthritis and lupus (Pennington et al., 2015).